Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1H68T | ISIN: US6951271005 | Ticker-Symbol: 82P
Frankfurt
31.03.25
16:08 Uhr
22,600 Euro
-0,600
-2,59 %
1-Jahres-Chart
PACIRA BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
PACIRA BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
22,80023,20022:03
22,80023,00022:00

Aktuelle News zur PACIRA BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.03.Pacira BioSciences, Inc. - 8-K, Current Report2
14.03.Pacira evaluates DOMA board nominees amid growth plans1
14.03.Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual2
06.03.Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)88PARSIPPANY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting...
► Artikel lesen
05.03.3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,1
05.03.Bull of the Day: Pacira BioSciences (PCRX)1
28.02.Pacira Q4 Earnings Top, Revenues Miss Despite Exparel Sales Growth5
PACIRA BIOSCIENCES Aktie jetzt für 0€ handeln
28.02.A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts2
28.02.H.C. Wainwright lifts Pacira stock target to $48 on Exparel outlook1
28.02.Pacira BioSciences Acquires Remaining 81% Equity Stake Of GQ Bio Therapeutics For About $32 Mln1
27.02.Pacira acquires GQ Bio to boost genetic medicine portfolio1
27.02.Pacira BioSciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
27.02.Pacira BioSciences, Inc. - 8-K, Current Report-
19.02.JPMorgan raises Pacira stock price target to $21 from $113
06.02.Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)112PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of...
► Artikel lesen
30.01.What 8 Analyst Ratings Have To Say About Pacira BioSciences1
30.01.Pacira upgraded at Truist citing end to eVenus patent dispute4
30.01.Pacira BioSciences Appoints Laura Brege As Chair Of The Board1
30.01.Pacira BioSciences, Inc. - 8-K, Current Report-
21.01.Pacira Names Brendan Teehan Chief Commercial Officer, Krys Corbett Chief Business Officer1
Seite:  Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1